Ximelagatran vs. Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis

MLA

Jean-Noel Fiessinger, et al. “Ximelagatran vs. Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis.” ACC Current Journal Review, vol. 14, May 2005, pp. 18–19. EBSCOhost, https://doi.org/10.1016/j.accreview.2005.04.020.

APA

Jean-Noel Fiessinger, Bruce L. Davidson, Jeffrey S. Ginsberg, Menno V. Huisman, Charles W. Francis, Scott D. Berkowitz, Henry Eriksson, Henri Bounameaux, & Torbjörn Lundström. (2005). Ximelagatran vs. Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis. ACC Current Journal Review, 14, 18–19. https://doi.org/10.1016/j.accreview.2005.04.020

Chicago

Jean-Noel Fiessinger, Bruce L. Davidson, Jeffrey S. Ginsberg, Menno V. Huisman, Charles W. Francis, Scott D. Berkowitz, Henry Eriksson, Henri Bounameaux, and Torbjörn Lundström. 2005. “Ximelagatran vs. Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis.” ACC Current Journal Review 14 (May): 18–19. doi:10.1016/j.accreview.2005.04.020.